Table 11.
Type of Nanosystems | Loaded Drugs | Diameter (nm) | Zeta Potential (mV) | PDI | Functional Modifications | Aimed Cells | Aimed Tumor | Animal Models | Ref |
---|---|---|---|---|---|---|---|---|---|
Hypoxia-sensitive liposome | Vinblastine-N-oxide (CPD100) | 142±4.16 | 155.4 ± 4.2 | 0.11±0.005 | A23187 | ES2 cells | Ovarian cancer | Female Swiss Webster mice | [323] |
Hypoxia-sensitive liposome | DOX | 181 ± 3 | −34.4 ± 1.3 | 0.34 ± 0.07 | Nitroimidazole derivative, | RM-1, FaDu cells | Hypoxic tumor | Cell line and patient-derived xenograft | [324] |
Liposome | DOX | 92.2±0.4 | −16.3 | 0.21±0.01 | Albumin-binding domain (ABD) | 4T1 | Breast cancer | Mice bearing 4 T1 tumors | [332] |
PH-sensitive liposome | HCQ, DOX | 121.89±1.59 | pH 7.4, −4.36 ± 0.16, pH 6.5, 12.12 ± 0.08 | – | TH peptide, RGD | B16F10, MCF-7 | – | B16F10 xenograft-bearing mice | [325] |
GSH- sensitive liposome | DOX | 65.2 ± 5.7 | –14.6 ± 3.3 | – | GSH | BxPC3, Huh7 | HCC\ poorly permeable pancreatic tumors | Mice bearing subcutaneous BxPC3 tumors | [333] |
MMP sensitive liposome (Cleavable) | DOX | 140 | −17.6 ± 0.6 | 0.059 ± 0.025 | PEG | PC3 cells | – | PC3 cells derived xenograft | [334] |
Liposome | DOX | – | – | – | Nanobowl | 4T1 | Breast tumor | Orthotopic 4T1 breast tumor mouse model | [335] |
Dual-layered Au-liposome | – | 72.84±22.49 | −17.7 | – | 64Cu\PEG | 4T1 | – | Orthotopic 4T1 breast tumor mouse model | [336] |
Targeting liposome | PTX | 112.5±4.1 | −34.4±0.8 | 0.25±0.009 | Ginsenosides | BGC-823 | Gastric cancer | BGC-823 cells derived xenograft | [337] |
Thermosensitive magnetic liposomes | Irinotecan, Fe3O4 | 193.7 ± 2.3 | 2.3 ± 0.1 | 0.22 0.01 | CET | U87 cell | Brain tumor | U87 cells derived xenograft | [338] |
PET imaging liposomes | 129.0 ± 2.2 | −16.53 ± 1.3 | – | Glucose- and DOTA-Cu2+ | A431 | – | A431 derived xenograft | [339] | |
Targeting liposome | DTX | 96.7±4.5 | – | Ginsenoside Rg3 | 4T1 | TNBC | Orthotopic TNBC model | [340] | |
Liposome | Clodronate | 101.8±24.4 | − 21 ± 5.04 | 0.2 | 4T1 cells | 4T1 breast cancer-bearing mice | – | [341] | |
Liposomes with targeted | Photochlor (HPPH)\ evofosfamide | 128.7 ± 75.0 | 29.97 ± 3.5 | – | Chitosan oligosaccharide | MDA-MB-231 | TNBC | MDA-MB-231 tumor model | [342] |
Dual-Targeting liposome | Cabozantinib\ IDO | 115.53±2.35 | 0.14±0.01 | 115.53±2.35 | – | 4T1 | TNBC | TNBC xenograft-bearing mice | [343] |
Liposome | DOX | 200 | – | – | Holo-Lf | 4T1 | – | 4T1 xenograft-bearing mice | [344] |
Liposome | ASOs | 150 ± 36 | −6.67 ± 0.18 | 0.0838 | Tumor-penetrating peptide, iRGD | 22Rv1, LNCaP, and VCaP | Bone metastasis model, 4T1 orthotopic tumor model | – | [345] |
Liposome | DMC | 40 | – | – | Pyrophaeophorbid | CT26 | Mice bearing CT26 tumor | Colorectal cancer | [346] |
PH-sensitive liposome | UA | 135.4 ± 0.636 | 7.8 | 0.3 | Chitosan | U14cell | [326] | ||
Targeting liposome | HAPO-1048, IR-1048 | 135.2 | –32.97±2.36 | – | HA | UM-UC-3 | Bladder cancer | Orthotopic BC model | [347] |
Targeting liposome | Honokiol | 162.6 ± 3.8 | −38.24 | 0.26 ± 0.02 | HA | 4T1 cells | Breast cancer | 4T1 tumor-bearing mouse model | [348] |
Abbreviations: HCQ, hydroxychloroquine; GSH, glutathione; CET, Cetuximab; DTX, docetaxel; TNBC, triple-negative breast cancer; IDO, Indoleamine 2,3-dioxygenase; Holo-Lf, holo-lactoferrin; ASOs, antisense oligonucleotides; HCC, hepatocellular carcinoma; ASOs, antisense oligonucleotides; DMC, demethylcantharidin; UA, ursolic acid.